Clinical trials
Phase 1/2 Pain trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 2 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Terminated | 7 |
| Withdrawn | 4 |
| Active, not recruiting | 3 |
| Recruiting | 2 |
| Suspended | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Florida | 2 |
| Albert Einstein College of Medicine | 1 |
| Austin V Stone | 1 |
| Baylor College of Medicine | 1 |
| Bioness Inc | 1 |
| Boston Scientific Corporation | 1 |
| CDA Research Group, Inc. | 1 |
| CMED HIFU Development Corporation | 1 |
| Center for Medicinal Cannabis Research | 1 |
| Cephalon | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pain | 42 |
| Osteoarthritis | 4 |
| Agnosia | 3 |
| Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Anemia, Sickle Cell | 2 |
| Breast Neoplasms | 2 |
| Chronic Pain | 2 |
| Headache | 2 |
| Inflammation | 2 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.